A large number of new drugs have been approved, highlighting the continuous improvement of the innovation capabilities of local pharmaceutical companies

The third quarter of 2021 is over
.
According to the drug approval document information issued by China's National Medical Products Administration (NMPA), as of September 29, more than 30 new drug listing applications of different categories have been approved in China in the third quarter
.
For these drugs, there are many imported new drugs, and the approved indications cover different disease fields such as cancer, autoimmune diseases, ophthalmology, and diabetes
.
It is worth mentioning that among about 20 imported new drugs, most of them are anticancer drugs
.
Of course, in addition to imported drugs, it can also be found that a number of Chinese original innovative drugs were approved for the first time in this quarter, including CAR-T products
.
Among them, there are even four types of new drugs developed by Chinese companies that have been approved.
They are from WuXi Junuo, Yuheng Biological, Kangfang Biological / Zhengda Tianqing, and Real Biological
.
It is reported that the approvals of these four new drugs are the first drugs approved for marketing by these four companies
.
In fact, with the exception of the third quarter, news that new drugs have been approved for marketing and applications have been accepted since the beginning of this year
.
According to statistics, under the background that the enthusiasm of various pharmaceutical companies for the research and development of innovative drugs has not diminished, as of now, the number of domestically produced Class 1 new drugs approved in the first half of 2021 has exceeded the entire year of 2020, a record high
.
In this regard, the industry believes that, on the whole, under the general trend of domestic pharmaceutical innovation, China's domestically produced innovative drugs have begun to market
.
In addition, this also means that China is constantly making breakthroughs in the research and development of new drugs
.
At present, after decades of development, the development of innovative drugs in China has moved from zero to follow-up innovation, and is accelerating to original innovation, that is, independent search for new drug targets and mechanisms of action
.
The industry predicts that according to domestic innovation trends, domestically-made innovative drugs and specialty drugs may become the main part of the domestic pharmaceutical market by 2030
.
At the same time, China’s pharmaceutical industry will accelerate from the era of generic drugs to a new era with innovative drugs as the main driving force.

.
However, it should be noted that the industry also pointed out that the development of China's innovative drug industry is still facing many challenges, such as serious homogeneity of targets, and high levels of duplication of products and product lines under development
.
Among them, the high repetition of popular targets is the main problem
.
This means that at present, China's pharmaceutical companies are doing more to follow quickly, and clinical research is also focused on fast-to-market targets and mechanisms of action, and there is still a lot of room for improvement in innovation
.
To truly improve the foundation of domestically-made innovative drug R&D and innovation capabilities, the industry believes that it lies in cultivating pharmaceutical talents with originality and ability
.
Relevant enterprises need to continuously incorporate professional talents, optimize their talent structure, improve their talent training mechanism, and formulate appropriate development strategies to usher in more vigorous development
.
In addition, as innovative drugs will usher in infinite structural opportunities, choosing differentiated or price-advantaged drugs for innovative research and development will also become crucial for pharmaceutical companies, and at the same time, will become their mainstay.
R&D trends
.